Leqvio 3-Month Second Dose: What to Expect at Day 90

What Happens at the Day-90 Appointment

The labeled dose is 284 mg as a single subcutaneous injection, given initially, again at 3 months, and then every 6 months [1]. The label specifies the same 284 mg for the initial injection and the 3-month injection and describes no separate dose or titration step for day 90 [1].

The label says Leqvio is administered by a healthcare professional into the abdomen, upper arm or thigh, and not into sunburned, rashy, inflamed or infected skin. It also says the solution should be inspected before use and should look clear and colorless to pale yellow [1].

Kidney and liver function do not change the dose: the label calls for no adjustment in mild, moderate or severe renal impairment, or in mild to moderate hepatic impairment. Inclisiran has not been studied in end-stage renal disease or in severe hepatic impairment [1].

What the Label Says LDL-C Is Doing by Day 90

The drug itself clears fast. After a 284 mg subcutaneous dose, plasma concentrations peak at about 4 hours and are undetectable by 24 to 48 hours, with a terminal half-life of about 9 hours and no accumulation with repeat dosing [1]. The label notes that LDL-C lowering persists for months after a dose despite this short plasma half-life [1]. Inclisiran is a small interfering RNA that directs breakdown of PCSK9 messenger RNA in liver cells, which increases LDL receptor recycling and LDL-C uptake from the blood [1].

In the label's pharmacodynamic data, a single 284 mg dose produced LDL-C reduction that was apparent within 14 days. After doses on day 1 and day 90, mean serum PCSK9 fell about 75% at day 120 and 69% at day 180 [1].

The large trials measured their primary LDL-C result at day 510, roughly 17 months in [3]. In ORION-10, which enrolled 1,561 adults with atherosclerotic cardiovascular disease on maximally tolerated statins, the placebo-corrected LDL-C reduction at day 510 was 52% [3]. In ORION-11, with 1,617 adults who had ASCVD or a risk equivalent, the placebo-corrected reduction was 50% [3]. In ORION-9, 482 adults with heterozygous familial hypercholesterolemia received inclisiran sodium 300 mg (equivalent to the 284 mg of inclisiran in the label) or placebo on days 1, 90, 270 and 450. At day 510, LDL-C fell 39.7% in the inclisiran group and rose 8.2% with placebo, a between-group difference of 47.9 percentage points [4].

Side Effects Reported in Clinical Trials

Across pooled adult trials, injection site reactions occurred in 8% of Leqvio-treated patients versus 2% with placebo, arthralgia in 5% versus 4%, and bronchitis in 4% versus 3% [1]. These percentages come from trial follow-up in which patients were treated for up to 18 months, not from the first three months alone [1].

The pooled data cover 1,833 adults on Leqvio, 1,682 of them exposed for 18 months (median 77 weeks), compared with 1,822 on placebo [1]. Adverse reactions led to discontinuation in 2.5% of Leqvio-treated patients versus 1.9% on placebo, and injection site reactions were the most common reason (0.2% versus 0%) [1].

Hypersensitivity is the label's only warning and precaution. Anaphylaxis and angioedema have been reported in patients treated with Leqvio, along with rash, pruritus and urticaria in post-approval reports. The label says patients should be advised of the signs and symptoms and to seek medical attention promptly [1]. A prior serious hypersensitivity reaction to inclisiran or any excipient is a contraindication [1]. There is no boxed warning [1].

In the 12-month pediatric trial in heterozygous familial hypercholesterolemia (141 patients aged 12 and older, 93 on Leqvio), the safety profile matched adults except for headache, reported in 13% of Leqvio-treated patients versus 6% on placebo [1]. On pregnancy, the label says to discontinue Leqvio when pregnancy is recognized, or alternatively to consider the patient's ongoing therapeutic needs [1].

If the Day-90 Dose Is Late

The prescribing information addresses late doses by how late they are. For a planned dose missed by less than 3 months, it describes administering the dose while maintaining the original schedule. When more than 3 months have passed, it describes restarting the initial, 3-month, then every-6-month schedule [1].

Who the Label Covers

Leqvio is labeled as an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia, in adults and children 12 and older with heterozygous familial hypercholesterolemia, and in children 12 and older with homozygous familial hypercholesterolemia [1]. The label notes that cardiovascular outcomes trials have shown LDL-C lowering reduces major adverse cardiovascular events when statins or PCSK9 monoclonal antibodies are added to a statin, but it reports no cardiovascular outcomes result for inclisiran itself [1].